WO2008091704A3 - Treatment of cushing's syndrome and autism - Google Patents

Treatment of cushing's syndrome and autism Download PDF

Info

Publication number
WO2008091704A3
WO2008091704A3 PCT/US2008/001030 US2008001030W WO2008091704A3 WO 2008091704 A3 WO2008091704 A3 WO 2008091704A3 US 2008001030 W US2008001030 W US 2008001030W WO 2008091704 A3 WO2008091704 A3 WO 2008091704A3
Authority
WO
WIPO (PCT)
Prior art keywords
cushing
syndrome
treatment
patient
autism
Prior art date
Application number
PCT/US2008/001030
Other languages
French (fr)
Other versions
WO2008091704A2 (en
Inventor
Vassilios Papadopoulos
Janet Greeson
Original Assignee
Univ Georgetown
Samaritan Pharmaceuticals Inc
Vassilios Papadopoulos
Janet Greeson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Samaritan Pharmaceuticals Inc, Vassilios Papadopoulos, Janet Greeson filed Critical Univ Georgetown
Publication of WO2008091704A2 publication Critical patent/WO2008091704A2/en
Publication of WO2008091704A3 publication Critical patent/WO2008091704A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Abstract

A method for the treatment of Cushing's syndrome in a patient in need thereof, the method comprising administering to the patient an effective amount of a combination of a pharmaceutically acceptable salt of procaine and zinc sulfate heptahydrate, at a frequency and for a duration of time sufficient to provide a beneficial effect to the patient.
PCT/US2008/001030 2007-01-25 2008-01-25 Treatment of cushing's syndrome and autism WO2008091704A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88664207P 2007-01-25 2007-01-25
US60/886,642 2007-01-25

Publications (2)

Publication Number Publication Date
WO2008091704A2 WO2008091704A2 (en) 2008-07-31
WO2008091704A3 true WO2008091704A3 (en) 2008-11-06

Family

ID=39645092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/001030 WO2008091704A2 (en) 2007-01-25 2008-01-25 Treatment of cushing's syndrome and autism

Country Status (1)

Country Link
WO (1) WO2008091704A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937286B1 (en) 2005-09-12 2016-03-09 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
JP5399072B2 (en) 2005-09-12 2014-01-29 アベラ ファーマスーティカルズ インコーポレイテッド System for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated therewith
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
AU2010313253B2 (en) 2009-10-30 2015-02-19 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
WO2011123695A1 (en) * 2010-03-31 2011-10-06 Abela Pharmaceuticals, Inc. Dimethy sulfoxxide (dmso) formulations for treating autism
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
CN108619127B (en) * 2017-03-21 2023-05-26 中国科学院分子细胞科学卓越创新中心 ALDH1A and uses of agonists, catalytic products and inhibitors thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085464A1 (en) * 1999-01-21 2005-04-21 Samaritan Pharmaceuticals Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085464A1 (en) * 1999-01-21 2005-04-21 Samaritan Pharmaceuticals Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAM ET AL.: "Neurochemical correlates of autistic disorder: A review of the literature", RESEARCH IN DEVELOPMENTAL DISABILITIES, vol. 27, 2006, pages 254 - 289, XP005399490 *

Also Published As

Publication number Publication date
WO2008091704A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2008091704A3 (en) Treatment of cushing's syndrome and autism
WO2007041398A3 (en) Treatment of cancer with specific rxr agonists
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
EP2295080A3 (en) B-cell reduction using CD37-specific and CD20-specific binding molecules
IL180992A0 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
EP1638624A4 (en) Medical devices and methods for regulating the tissue response to vascular closure devices
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006102374A3 (en) Bioactive wide-weave mesh
HK1123213A1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
WO2012017166A3 (en) Benzenesulfonamide-compound treatment of a pathological condition linked to an excessive effect of tnf
WO2009079451A3 (en) Compositions and methods of promoting wound healing
EP1771188A4 (en) Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2007149283A3 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
EP1902715A3 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
PL2640364T3 (en) Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiasis and related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08724844

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08724844

Country of ref document: EP

Kind code of ref document: A2